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Acute myeloid leukemia (AML) is a clinically and molecularly heterogeneous disease with
poor outcome. Adequate model systems are required for preclinical studies to improve un-
derstanding of AML biology and to develop novel, rational treatment approaches. Xeno-
grafts in immunodeficient mice allow performing functional studies on patient-derived AML
cells. We have established an improved model system that integrates serial retransplanta-
tion of patient-derived xenograft (PDX) cells in mice, genetic manipulation by lentiviral trans-
duction, and essential quality controls by immunophenotyping and targeted resequencing
of driver genes. 17/29 samples showed primary engraftment, 10/17 samples could be
retransplanted and some of them allowed virtually indefinite serial transplantation. 5/6 sam-
ples were successfully transduced using lentiviruses. Neither serial transplantation nor ge-
netic engineering markedly altered sample characteristics analyzed. Transgene expression
was stable in PDX AML cells. Example given, recombinant luciferase enabled biolumines-
cence in vivo imaging and highly sensitive and reliable disease monitoring; imaging visual-
ized minimal disease at 1 PDX cell in 10000 mouse bone marrow cells and facilitated
quantifying leukemia initiating cells. We conclude that serial expansion, genetic engineering
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and imaging represent valuable tools to improve the individualized xenograft mouse model
of AML. Prospectively, these advancements enable repetitive, clinically relevant studies on
AML biology and preclinical treatment trials on genetically defined and
heterogeneous subgroups.
Introduction
Acute myeloid leukemia (AML) remains a hematologic malignancy with poor outcome. There
is a strong demand for preclinical models to develop novel, targeted therapies based on a better
understanding of the complex biology of AML [1]. Although a multitude of tumor cell lines
exist [2], important functional characteristics may be altered in cell lines during the process of
immortalization [3]. Work with primary tumor cells represents an attractive alternative more
closely related to the patient, but primary AML cells rarely show sustained growth in vitro, de-
spite improvements using cytokine-based co-culture systems [4].
To allow in vivo studies on AML, engraftment of patient-derived cells in immuno-compro-
mised mice has been established in the early 1990s using severe combined immunodeficiency
(scid) mice [5–7]. Engraftment capacity had improved by using more severely immuno-com-
promised mice such as the Non-Obese Diabetic (NOD)/scid mice [8–12] and lately NOD/scid
IL2 receptor gamma chain knockout (NSG) mice, which virtually lack B, T, and functional NK
cells [13–19].
Using the individualized xenograft mouse model of AML has resulted in seminal insights,
e.g., in stem cell biology [20,21]; nevertheless, the model has not yet been used extensively for
other purposes. First, most studies were performed on mice injected with primary patient cells,
while retransplantation of engrafted AML cells was restricted to studies analyzing stem cell fea-
tures and self-renewing capacity [9,10,17,19]. Nevertheless, serial retransplantation is highly at-
tractive as it provides a continuous supply of patient-derived xenograft (PDX) AML cells for
repetitive functional and therapeutic studies both in vitro and in vivo, but this approach has
not yet been systematically explored. Second, genetic engineering was never reported in estab-
lished PDX AML cells. Molecular studies were mainly restricted to AML cell lines, which were
genetically altered both for in vitro and in vivo studies, and both for knockdown strategies and
transgene overexpression, including in vivo imaging [22–24]. Nevertheless, PDX AML cells
represent a highly interesting tool for molecular studies, e.g., on signaling proteins, due to their
close relationship to the patient sample, in contrast to established AML cell lines. Thirdly,
monitoring the growth characteristics of PDX cells in vivo is an important readout for preclini-
cal studies, yet this remains challenging as PDX cells are detected in mouse peripheral blood
(PB) only at late disease stages using flow cytometry or polymerase chain reaction [16,17,19],
and repetitive bone marrow (BM) aspirations are performed infrequently for animal welfare
[25,26]. Analysis of murine inner organs like spleen, liver, and kidney can only be performed
post mortem [16,17,19], which constitutes a major disadvantage in preclinical treatment trials
[27].
Serial passaging and genetic engineering have already been established in studies using pri-
mary tumor cells from patients with acute lymphoblastic leukemia (ALL) by others and us and
have proven to be valuable tools to facilitate preclinical in vivo studies [28–31].
The aim of the present work was to develop an improved preclinical mouse model of AML,
broadening and increasing the use and quality of studies performed in the model, by: (i) per-
forming serial retransplantation of primary AML cells to repetitively provide PDX cells for in
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vitro and in vivo studies; (ii) introducing genetic engineering of PDX cells to express transgenes
using lentiviral transduction; (iii) introducing repetitive and sensitive disease monitoring in
vivo by bioluminescence imaging (BLI) and; (iv) establishing a stringent set of quality controls
to monitor the effect of retransplantation and transgene expression on molecular, phenotypic
and functional sample characteristics. Due to these advances, our model system will facilitate
future studies on AML biology and novel treatment approaches in vivo.
Methods
Primary AML cells
Fresh BM or PB samples from adult AML patients were obtained from the Department of In-
ternal Medicine III, Ludwig-Maximilians-Universität, Munich, Germany, during the years
2012 and 2013. Specimens were collected for diagnostic purposes before start of treatment.
Written informed consent was obtained from all patients or legal guardians in the cases where
patients were minors. The study was performed in accordance with the ethical standards of the
responsible committee on human experimentation (written approval by Ethikkommission des
Klinikums der Ludwig-Maximilians-Universität, Munich, number 068-08) and with the Hel-
sinki Declaration of 1975, as revised in 2000. Pediatric AML samples were described previously
[19].
Mice
NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ (NSG; The Jackson Laboratory, Bar Harbour, ME, USA)
were maintained under specific pathogen-free conditions in the research animal facility of the
Helmholtz Zentrum München, Munich, Germany. Animals had free access to food and water,
and were housed with a 12-hour light–dark cycle and constant temperature. All animal trials
were performed in accordance with the current ethical standards of the official committee on
animal experimentation (written approval by Regierung von Oberbayern, number 55.2-1-54-
2532-95-10). When clinical signs of illness became apparent (more than 60% leukemic cells
within PB, rough fur, hunchback, or reduced motility), mice were sacrificed equally in all pas-
sages. If leukemia became not apparent, mice were killed and analyzed 25 weeks after cell injec-
tion by latest.
Recovering PDX cells from mice and serial transplantation
From first generation mice harboring primary AML cells (see S1 Methods), PDX cells were rei-
solated out of femurs, tibiae and spleen by mincing the tissues and filtration through a cell
strainer, followed by Ficoll gradient centrifugation in case of splenic cells. PDX AML cells were
identified by staining for human CD45, CD33, CD3 and CD19 and flow cytometry analysis
(see S1 Methods). Without further enrichment or manipulation, 1x106–1x107 total BM cells
were reinjected into next recipient NSG mice for reexpansion (secondary transplantation).
Targeted next generation deep sequencing
Genetic characterization of patient specimens and PDX cells was performed using a targeted,
multiplexed amplicon resequencing approach (Haloplex, Agilent, Boeblingen, Germany). Mu-
tational hotspots or the entire coding sequences, as appropriate, of 43 genes known to be recur-
rently mutated in myeloid malignancies (S1 Table) were amplified from 250 ng of genomic
DNA. The resulting libraries were sequenced on an Illumina MiSeq instrument (Illumina, San
Diego, USA) using 2x250 bp paired-end reads. Sequence data were aligned to the human refer-
ence genome (version hg19) using BWA [32]. Single nucleotide variants and short insertions
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or deletions were called using the VarScan 2 [33] and Pindel algorithms [34], respectively,
using a custom data analysis pipeline. Known and putative leukemia-associated mutations
were identified through a review of published data and public databases including COSMIC
and dbSNP, and novel variants were assessed based on their functional consequences on the
amino acid level (i.e., nonsense and frameshift mutations were considered pathogenic). A vari-
ant allele frequency (VAF) of 2% was used as the threshold for mutation calling.
Statistical analysis
Mean and standard deviation of the mean were calculated using the Microsoft Excel 2010 soft-
ware (Microsoft, Redmont, WA, USA). LIC frequencies were calculated according to Poisson
statistics using the ELDA software application (http://bioinf.wehi.edu.au/software/elda).
Additional Methods
Please refer to S1 Methods for description on first engraftment of primary AML cells in NSG
mice; monitoring engraftment of PDX cells by flow cytometry analysis of PB; surface antigen
characterization of PDX AML cells by flow cytometry; cloning; lentiviral transduction; enrich-
ment of transgene-expressing cells; in vivo bioluminescence imaging (BLI); quantification of
BLI pictures; and Limiting dilution transplantation assay (LDTA).
Results
The aim of the present work was to develop the individualized mouse model of AML further
and increase its capabilities for future in vivo studies on AML biology or treatment efficiency of
novel therapeutic strategies.
High consistency of AML-specific mutations between primary and PDX
AML cells
According to published protocols [6,16,17,19,35], we transplanted cells from 29 adult patients
with AML. Patients' clinical characteristics are depicted in Table 1. In line with published data,
17/29 (59%) samples engrafted in NSG mice, defined by more than 0.1% hCD45+ hCD33+
cells within BM within 20 weeks after transplantation [17,35–38], although with broad differ-
ences regarding in vivo growth characteristics (Fig. 1; Table 1; see S1 Results for details).
AML is a genetically heterogeneous group of diseases, and various gene mutations have
been shown to be associated with treatment response and patient outcome [39]. Furthermore,
AML patients may harbor multiple, genetically related disease subclones [40,41]. The benefit of
using patient-derived cells in preclinical in vivomodels depends on their ability to faithfully re-
capitulate the genotypic heterogeneity of the disease. Thus, we performed comprehensive anal-
yses as quality controls, as proposed recently [41]. Using a targeted resequencing approach that
covers 43 genes with known roles in AML pathogenesis (S1 Table), we studied six primary pa-
tient samples and matched xenografts. Per sample, we identified two to six mutations (Fig. 2,
Fig. 3F; S2 Table). Each patient sample contained mutations with a variant allele frequency
(VAF) of close to 50%, indicating that these variants were present in most cells, assuming het-
erozygosity. All of these mutations, which mark the founding clone of the AML cell population,
were preserved in the PDX cells recovered from mice after amplification, consistent with data
published previously [41]. In each primary sample, we detected additional mutations with a
significantly lower VAF, suggesting the presence of subclones within the AML cell population
[41,42]. Most of these mutations were also detected within the respective PDX cells. In two
cases, we observed an increase in the VAF of mutations in PDX compared to primary cells,
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indicating that the subclone carrying the mutation had an engraftment or growth advantage
(AML-361 and AML-393; Fig. 2 and Fig. 3F). Four samples showed evidence of polyclonal en-
graftment. In these cases, variants found in the patient at a low VAF were detected in PDX cells
Table 1. Patients’ clinical characteristics.
Sample Tx Re- FAB Disease Cytogenetics NPM1 FLT3 ELN Sex Age PB/ Blasts
Tx stage [y] BM [%]
AML-361 AML 5* M4 Initial Normal Mut ITD Int I F 40 PB 42
AML-372 AML 6* M0 Relapse Complex, WT WT Adv M 42 PB 67
after SCT Including −17
AML-373 AML 1 M2 Initial Normal WT WT Int I F 79 PB NA
AML-390 AML 3* M4 Initial ND WT WT NA F 62 BM 70
AML-393 AML 5* M4 Relapse 46,XX, WT WT Adv F 47 BM 54
after SCT ins(10;11)
(p12;q23q23)
AML-407 AML 1* M0 Relapse 47,XX,t(4;8) WT WT Adv F 58 PB 34
after SCT (p15;q22),+12
AML-412 AML 4* M1 Initial Normal Mut ITD Int I F 65 BM 96
AML-415 AML 2* NA Relapse Normal Mut ITD Int I F 68 BM NA
AML-469 AML 1* M4 Initial 47,XY,+8 WT ITD Adv M 25 PB 83
AML-491 AML 3* NA Relapse Aberrant WT WT Adv F 53 PB 44
AML-343 AML 0 NA Initial Normal Mut ITD Int I M 79 PB NA
AML-362 AML 0 M4 Initial Normal Mut WT Fav M 71 BM 60
AML-392 AML 0 M2 Initial NA WT ITD NA F 65 BM 25
AML-396 AML 0 M4 Initial Aberrant WT WT Adv M 73 BM 42
AML-403 AML 0 M1 Initial 46,XX, WT WT Adv F 33 BM 80
del(12)(p13)/
48,XX,+3,+18
AML-426 AML 0 NA Relapse Normal WT ITD Int I F 55 PB 29
AML-452 AML 0 M1 Initial Normal Mut ITD Int I F 82 PB 93
AML-353 B NA M5A Initial Complex Mut WT Adv M 74 PB 46
AML-405 B NA M1 Initial NA Mut ITD NA M 51 PB 89
AML-410 T NA M4 Initial Normal Mut WT Fav M 35 BM 47
AML-397 T NA NA Initial 47,XY,+8 WT WT Adv M 73 PB 42
AML-342 None NA M1 Initial Normal Mut ITD Int I F 82 PB 69
AML-345 None NA M1 Initial Normal WT ITD Int I F 54 PB 90
AML-348 None NA M4 Initial Normal Mut ITD Int I M 58 BM 60
AML-391 None NA NA Initial 47,XY,+13 WT WT Adv M 62 BM 46
AML-401 None NA M1 Initial 46,XY,t(11;14) Mut WT Adv M 73 PB 78
(q13;q32)
AML-421 None NA M1 Initial Normal Mut WT Fav F 47 BM 67
AML-433 None NA NA Initial Normal Mut WT Fav F 48 BM 67
AML-441 None NA NA Relapse Complex WT WT Adv M 43 BM 78
Tx (nature of human cells isolated after initial transplantation); Re-Tx (amount of passages of successful re-transplantation)
* (next passage in progress during manuscript preparation); T (T cells); B (B cells); FAB (French–American–British classification system); SCT (stem cell
transplantation); NPM1 (nucleophosmin-1); WT (wildtype); Mut (mutated); FLT3 (Fms-related tyrosine kinase 3); ITD (internal tandem duplication); ELN
(European LeukemiaNet classification system); Fav (favorable); Int I (intermediate I); Adv (adverse); F (female); M (male); PB (peripheral blood); BM
(bone marrow); NA (not available); ND (not determined).
doi:10.1371/journal.pone.0120925.t001
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Fig 1. Engraftment of primary AML cells in NSGmice predicts reengraftment capacity. 107 fresh
primary AML cells were injected and successfully engrafted in NSGmice; shown are characteristics of the
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with similar, low allelic frequencies, that were highly consistent between multiple mice trans-
planted in parallel (AML-372, AML-373, AML-407, and AML-412; Fig. 2). In two samples,
small subclones (VAFs of the subclone-specific mutations below 10%) were detected in the pa-
tient sample but were undetectable in mice (AML-373 and AML-412). These subclones may
have had a relative engraftment or proliferation disadvantage in our model. In one sample
from a patient with a FLT3-ITD (60bp length), we detected a second, additional FLT3-ITD
(96 bp length) in PDX cells obtained from three mice injected in parallel (VAF 2–4%). This
second mutation was not detectable in the primary specimen (AML-373). Since the same, addi-
tional FLT3-ITD emerged in all three mice that were inoculated with the patient’s cells in paral-
lel, we conclude that a small subclone carrying this variant was present in the patient sample,
albeit below our limit of detection. After xenotransplantation, the subclone carrying the 96bp
FLT3-ITD expanded relative to the 60bp FLT3-ITD-mutated clone, and thus had an engraft-
ment or growth advantage in our model. Our data are in line with published results describing
the challenge of reliably mimicking rare subclones upon xenotransplantation [41].
These results illustrate several important characteristics of our model: (i) driver mutations
present in the founding clone of primary AML specimens are preserved in xenografts; (ii) cer-
tain subclones present within the patients’ primary cell population may have an engraftment
or growth advantage or disadvantage in mice, as indicated by the increase or decrease, respec-
tively, of the VAF in PDX cells compared to the patient sample; (iii) in the three samples that
were xeno-transplanted in multiple mice in parallel, engraftment characteristics of subclones
are reproducible; (iv) PDX cells do not gain mutations in the studied AML driver genes, if they
were unmutated in the patient's specimen.
Serial transplantation of PDX AML cells
Next, capacity of initially engrafted cells to reengraft in next generation recipient mice was ana-
lyzed. 10/17 (59%) of established PDX samples, corresponding to 10/29 (34%) of all trans-
planted samples, reengrafted after first retransplantation. As positive predictive markers for
successful repassaging, we identified the following growth characteristics of primary cells in the
first transplantation: (i) overt leukemia in mice within 20 weeks after cell injection, accompa-
nied by (ii) a substantial percentage of human cells in mouse BM and (iii) more than 5% leuke-
mic cells in the blood at time of sacrifice (Fig. 1, S1B Fig.). A threshold of 0.1 to 1% human cells
within BM to define positive engraftment, as proposed by others [10,17,35–38], was not suffi-
cient to reengraft these cells in our hands, and might be explained by the absence of long-term
LICs.
Furthermore, serial transplantation of PDX cells was evaluated, to enable repetitive and re-
producible experiments. Samples were retransplanted in up to six consecutive generations of
mice. Until now, 6 samples could be analyzed for capacity to reengraft serially for more than
three passages. 5/6 (83%) samples engrafted serially in all retransplantation experiments per-
formed (S2 Fig.). Only one specimen (AML-373) did not allow retransplantation for more
than one cycle. These results are in line with published data where successful secondary and
tertiary engraftment was used as prove for the presence of long-term LICs which were not pres-
ent in all AML samples [9].
first engraftment regarding passaging time (time period from cell injection until clinical signs of leukemia or
latest between 20 and 25 weeks) (A); percentage of cells positive for both hCD45 and hCD33 at time of
sacrifice within mouse PB (B) and within BM (black cubes) or spleen (grey circles) (C). Each mark visualizes
data obtained from a single mouse. Open cubes indicate 0% human cells. Dotted line discriminates samples
that reengrafted in secondary recipients from samples that did not. Please refer to S1A Fig. for exemplary
FACS plots.
doi:10.1371/journal.pone.0120925.g001
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Fig 2. Engraftment and retransplantation of AML cells in NSGmice conserves genetic alterations of the primary sample. Primary AML patient
samples and matched PDX cells, reisolated out of the BM (CD45 chimerism 80–99%) after first passage in NSGmice (PDX-0) or after 1 or 2 re-
transplantation cycles (PDX-1/-2), were characterized by targeted resequencing of 43 AML-related genes (S1 Table). Plots depict variant allele frequencies
for each driver gene mutation found within the sample. a/b/c/d/f: PDX cells of three to five mice injected in parallel were analyzed. *: primary cells were frozen
and thawed before injection. BCOR (BCL-6 corepressor); CEBPA (CCAAT/enhancer binding protein alpha); DNMT3A (DNA (cytosine-5)-methyltransferase
3 alpha); FLT3 (Fms-related tyrosine kinase 3); ITD (internal tandem duplication); KRAS (Kirsten rat sarcoma viral oncogene homolog); NPM1
In vivo Imaging of Xenografted Patients' AML Cells
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Serial reengraftment of PDX AML samples was further characterized. Similar between all
samples, murine BM consisted mainly of human leukemic cells at time of overt illness (mini-
mum 80%, maximum 99.8%). In contrast, other characteristics varied widely between samples,
including passaging time (minimum 4 weeks, maximum 15 weeks), percentage of leukemic
cells in PB (minimum 1%, maximum 99.8%), or amount of leukemic cells in the spleen (mini-
mum 1x106, maximum 7x108) (S2 Fig.). Splenic enlargement was observed in one sample
(AML-393), while all other samples showed only minor infiltration of the spleen. This is in
contrast to PDX ALL cells, where splenomegaly represents a common feature between all sam-
ples and 1x108 human cells can regularly be reisolated out of the spleen [31], but consistent
with other studies analyzing AML engraftment in NSG mice [17].
Serial transplantation might affect clonal composition of PDX cells. Targeted resequencing
of serially transplanted cells revealed that they still contained the same leukemia-associated
mutations as primary patient specimens and PDX cells after initial engraftment (Fig. 2; S2
Table). In addition, analysis of six AML associated antigens revealed that the immunopheno-
type of PDX cells after four retransplantations was similar to the primary specimens for most
antigens tested (Fig. 3E, S3 Fig.; S3 Table). Thus, serial expansion did not severely alter molecu-
lar sample characteristics of AML cells, indicating that PDX cells closely resemble the disease
they originate from.
Genetic engineering in AML PDX cells
Until now, preclinical studies in AML were restricted to established AML cell lines [22–24], al-
though they might inherit unphysiologic mutations acquired upon prolonged in vitro culture.
The use of PDX AML cells will allow repetitive molecular studies on cells highly related to the
patients, but these cells have never been used for genetic engineering so far.
Here, we established lentiviral transduction of PDX AML cells, which we and others had
successfully used to genetically modify PDX ALL cells [28–31] or primary AML cells [9]
(Fig. 3A), although lentiviral transduction holds the risk of additional untargeted genetic alter-
ations [43]. Lentiviral constructs coding for, e.g., luciferase and the red fluorochrome mCherry
or the antigene nerve growth factor receptor (NGFR), were cloned under the control of the
EF1-alpha promoter; transgenes were connected by a T2A linker allowing equimolar expres-
sion (Fig. 3B).
Four PDX samples from adult AML patients as described above (AML-361, AML-372,
AML-393, AML-412) were included into further studies together with two pediatric PDX sam-
ples (AML-346, AML-356) that had been engrafted and serially transplanted before [19] (S4
Table). After transduction and reamplification in mice, percentage of transgenic PDX (t-PDX)
cells was determined by flow cytometry. For one sample (AML-361), no transgenic cells were
detectable after six independent transduction trials. Within the other five samples, transduc-
tion efficiency ranged from 1.1% to 90% (Fig. 3C). Although defined factors determining lenti-
viral transduction efficiencies could not be identified, specific characteristics of samples,
constructs and viruses might influence the process. t-PDX cells were enriched by flow cytome-
try (Fig. 3D) or by magnetic-activated cell sorting (MACs), and were reinjected into another
generation of recipient mice (Fig. 3A). To generate samples with a high percentage of transgen-
ic cells (>90%), transgenic cells were enriched by two rounds of cell sorting. As some samples
were transduced with a rather low transduction efficiency (Fig. 3C), cell enrichment inherits
the threat of clonal selection, as we could not guarantee that all subclones of a sample have
(nucleophosmin-1);NRAS (neuroblastoma RAS viral oncogene homolog); SRSF2 (serine/arginine-rich splicing factor 2); TET2 (tet methylcytosine
dioxygenase 2); TP53 (tumor protein p53). Raw data is depicted in S2 Table.
doi:10.1371/journal.pone.0120925.g002
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Fig 3. PDX AML cells allow genetic engineering without alteringmolecular sample characteristics. (A) Scheme of the process of generating
transgenic PDX (t-PDX) AML cells. PDX cells were transduced after first or second retransplantation cycle. (B) Scheme of the vector constructs. (C)
Transduction rate in t-PDX AML cells after lentiviral transduction and cell amplification in mice was measured by FACS analysis of fluorochrome or NGFR
expression. Each mark visualizes data obtained from a single transduction. Open mark: no transgenic cells were detectable. (D) Enrichment of transgenic
In vivo Imaging of Xenografted Patients' AML Cells
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been transduced equally. Nevertheless, lentiviral transduction and cell enrichment did not
markedly alter sample characteristics like growth behavior and immunophenotype in t-PDX
compared to PDX AML cells or primary specimens, respectively (Fig. 3E, S4A Fig.; S3 Table).
Furthermore, the mutational pattern within the defined set of AML driver mutations studied
and within the resolution applied was not altered in the 2 samples analyzed, apart from a loss
of a rare subclone carrying an NRASmutation (VAF 5%) in t-PDX of AML-372 (Fig. 3F; S2
Table). Transgene expression level remained stable over numerous consecutive transplanta-
tions (S4 Fig.). In contrast, CMV promoters were silenced in our ALL model within a short pe-
riod of time (own unpublished data).
Taken together, lentiviral transduction was feasible in 5/6 (83%) PDX samples; both lenti-
viral constructs allowed successful transduction indicating a more general applicability of lenti-
viral constructs. Cell enrichment allowed generation of t-PDX cells without markedly altering
sample characteristics. Successful genetic engineering in PDX AML cells now opens a broad va-
riety of possible molecular studies.
Highly sensitive repetitive BLI of t-PDX AML cells in single mice
We next wanted to evaluate transgene expression in PDX cells and used the expression of lucif-
erase as both a convenient example system and an attractive target protein. Expression of lucif-
erase enables in vivo bioluminescence imaging (BLI) for sensitive and repetitive disease
monitoring in single living mice over time [44]. BLI would greatly improve analysis of preclini-
cal treatment trials in the individualized mouse model of AML. Until now, monitoring of dis-
ease development and treatment efficiencies was hampered by the lack of sensitive and
repeatable detection procedures.
A codon-optimized form of firefly luciferase (effluc) was used which enables intense light
emission for sensitive monitoring [45]. BLI is frequently and successfully used in tumor cell
lines to monitor growth or treatment response in vivo [46–50] or to monitor engraftment of
human hematopoietic stem cells in mice [51]. We and others have recently established BLI to
monitor PDX ALL cells growing in mice [28–31], while BLI could not be performed in PDX
AML cells so far due to the lack of genetic engineering.
1x105 t-PDX cells of AML-372 were injected into mice and repetitively monitored using BLI
(Fig. 4A, S5A Fig.). One day after cell injection, positive BLI signals were visible in the liver and
the lower extremities most probably emitted by the BM (S5A Fig.). BLI signal persisted and in-
creased within the legs over time. The liver signal observed shortly after cell injection vanished
after another day and might be due to AML blasts that had intermediately homed to the liver,
but left the liver again. After ten days, BLI allowed detection of signal in the upper extremities
and the sternum. Only at late time points close to animal death, BLI visualized t-PDX AML
cells in the spleen (Fig. 4A), reproducing our experience that splenic involvement is difficult to
visualize in BLI [31].
When BLI signals were quantified, signal intensity increased exponentially over time imply-
ing logarithmic growth of PDX AML cells in mice, which is identical to results obtained for
ALL [31]. Over time, BLI signal increased by more than four orders of magnitude, enabling a
broad range of BLI signals for sensitively discriminating different AML tumor burdens. By
cells using flow cytometry was measured using mCherry expression after cell amplification in mice. (E)Genetic engineering does not alter
immunophenotype; primary cells, untransduced PDX cells after fourth retransplantation and enriched transgenic t-PDX cells were analyzed by multicolor flow
cytometry; specific fluorescence intensity is depicted. See also S3C Fig. for exemplary FACS plots of AML-372. Raw data is depicted in S3 Table. (F)
Genetic engineering does not markedly alter AML-specific mutations; genomic DNA was isolated out of primary cells, untransduced PDX cells and enriched
transgenic t-PDX cells; VAF of mutations was profiled by targeted resequencing. BCOR (BCL-6 corepressor); KRAS (Kirsten rat sarcoma viral oncogene
homolog); NRAS (neuroblastoma RAS viral oncogene homolog); TP53 (tumor protein p53). Raw data is depicted in S2 Table.
doi:10.1371/journal.pone.0120925.g003
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Fig 4. BLI is highly sensitive and reliable in single mice. (A) 1x105 t-PDX AML-372 cells were injected into two mice. At indicated days after cell injection,
mice were monitored by BLI. Images of one representative mouse are shown. See S5A Fig. for further images. (B) BLI signals from the kinetic in A were
quantified in both animals (diamonds); cells positive for both hCD45 and hCD33 in PB were analyzed in parallel (circles). (C) t-PDX AML-372 cells were
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using BLI, we were able to visualize AML growth in mice markedly earlier than by flow cytom-
etry measurement in PB, where human cells were detectable not before six weeks after cell in-
jection (Fig. 4B). Furthermore, BLI using effluc-t-PDX cells seems to be more sensitive and
covers a broader range than imaging applying Alexa Fluor 680-labeled monoclonal antibodies
[52].
To determine the sensitivity of BLI, different amounts of t-PDX AML cells were injected
and mice were imaged as early as 18 hours after cell injection. Application of 1x105 (3/3 mice)
and 3x104 (2/3 mice) t-PDX AML cells resulted in a positive BLI signal at both femurs, whereas
1x104 cells yielded no detectable signal (Fig. 4C). Thus, PDX AML cells seem to home to the
mouse BM within few hours. Assuming that (i) each mouse has about 3x108 BM cells in total
(see supplemental results for calculation of this value) and that (ii) within 18 hours from injec-
tion 100% of injected t-PDX cells had successfully homed to the BM, but (iii) cells had not yet
started to proliferate, BLI was able to visualize less than 30000 leukemia cells per mouse, hence
one human cell among 10000 murine BM cells (0.01%). As homing efficiency is unlikely to
reach 100%, BLI probably is even more sensitive.
Thus, expression of luciferase in PDX AML cells enables repetitive BLI for highly sensitive
visualization of t-PDX cells in mice at tumor burdens which range within the different defini-
tions of minimal residual disease in AML patients [53], to analyze homing efficiency of PDX
cells into the BM niche, and for convenient monitoring of leukemia development in vivo.
BLI for quantifying leukemia stem cell surrogates
AML represents a stem cell disease, and various scientific questions require quantification of
leukemia initiating cells (LIC) as stem cell surrogates [20]. The gold standard method for deter-
mining LIC frequency is the limiting dilution transplantation assay (LDTA) [6,36,37,54–57].
LDTAs are usually quantified by post mortem analysis of numerous mice on the same day, e.g.,
16 weeks after cell injection, and thus evaluating a single time point. We validated the use of
BLI for monitoring LDTA over time.
Limiting numbers of t-PDX AML-372 cells were injected into groups of mice and repetitive
BLI was performed in all animals (Fig. 5A). Reproducing results obtained before, 2/3 mice re-
ceiving 3x104 cells were positive in BLI one day after cell injection (S5B Fig.). Seven days later,
2/3 mice of the next dilution (1x104 cells) became positive in BLI; at day 29 after cell injection,
all mice that would ever engraft were positive in BLI (Fig. 5A-B; S5 Table). Calculation of LIC
frequency showed a clear time-dependent increase, which remained stable as early as four
weeks after cell injection (Fig. 5C). Similar results were obtained in t-PDX AML-346 cells (S6
Fig.; S6 Table). LIC frequencies were 1 in 5.1x103 (AML-372) and 1 in 2.8x103 (AML-346),
consistent with data obtained from sorted primary AML samples [56]. Thus, BLI enabled reli-
able determination of LIC frequencies in LDTAs within short periods of time.
Discussion
In the present work, we developed the individualized xenograft mouse model of AML further
by evaluating serial transplantation and introducing lentiviral transduction and biolumines-
cence imaging. As these technical advances did not markedly alter important sample character-
istics such as AML-specific mutations and growth behavior, the advanced model now
injected into three mice per group at absolute numbers indicated; 1 and 8 days after cell injection, mice were monitored by BLI; images are shown of one
representative mouse per group.
doi:10.1371/journal.pone.0120925.g004
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Fig 5. BLI facilitates quantifying leukemia stem cell surrogates. After limiting dilution of t-PDX AML-372 (98% hCD45+ hCD33+mCherry+), cells were
injected into three mice per group (12 mice total) at absolute cell numbers indicated; leukemia development was monitored by BLI over time. (A) Images of
one representative mouse per group. See S5B Fig. for further images. (B) BLI signals from the kinetic in A were quantified. Shown are mean values plus/
minus standard deviation. (C) LIC frequency was calculated at each time point using ELDA software. Raw data is depicted in S5 Table.
doi:10.1371/journal.pone.0120925.g005
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represents a highly attractive tool for future in vivo trials on AML biology and novel
treatment strategies.
The individualized xenograft mouse model of AML has been used in the past with a focus
on primary transplantation and analysis of stem cell surrogates [25,36,38,57–60]. Retransplan-
tation experiments have mainly been performed to verify self-renewal capacity of engrafted
cells [9,10,16,17,19,37,56], or to analyze stability of gene expression profiles [19], but not for
studies on AML biology or therapy. In parallel to the successful use of individual ALL PDX
cells in preclinical trials [28–31,54], our data suggest broadening the use of the individualized
AML mouse model for work on serially transplanted PDX cells. We suggest, however, to quali-
ty control PDX cells in comparison to the primary specimen and between different passages
concerning AML-characteristic mutations, immunophenotype and functional characteristics
like passaging time and organ-specific engraftment rates, as some alterations in mutational or
antigen expression patterns might occur during (serial) engraftment.
The value of using the individualized mouse model as preclinical model depends on the ca-
pability of PDX cells to faithfully mimic the heterogeneity of the disease. Published results
showed that PDX cells resemble the primary samples concerning gene expression profiles
[10,11,15,19]. Accordingly, in our hands, AML sample-specific characteristics like surface anti-
gen expression or growth behavior in mice remained mainly stable upon serial transplantation
and lentiviral transduction. Recently, genetic stability of xenografted AML cells has been ana-
lyzed in detail [41]. The authors saw that founding clone mutations were preserved in PDX
cells, but that subclonal architecture was often not reflecting the primary sample. The authors
proposed that xenotransplantation models should be controlled by characterizing the genotype
of AML cells both before and after xenotransplantation. Therefore, we performed targeted
resequencing, to reveal if genetic alterations in PDX AML cells are comparable to the primary
sample, not only upon first engraftment as studied recently [41], but also after serial transplan-
tation and after genetic engineering. In agreement with published data [41], we found that
AML driver gene mutations present in the founding clone of the AML cell population were
preserved in PDX cells, but skewing of the subclonal architecture occurred in certain samples.
Of note, we observed polyclonal engraftment in several patient samples, and the size of engraft-
ing subclones (estimated from the VAF of subclonal mutations) was highly reproducible when
multiple mice were injected in parallel. Furthermore, certain subclones appear to have engraft-
ment advantages or disadvantages and might be lost or expand upon engraftment, either due
to evolutionary procedures also present in patients or due to altered selection pressure factors
within the mouse compared to the human microenvironment. From our data, we conclude
that current mutations that characterize the founding clone are faithfully recapitulated upon
xenotransplantation in mice and can be reliably studied in preclinical trials.
Serially transplantable PDX cells offer important advantages compared to existing tradition-
al AML cell lines, as cell lines may not be representative for the heterogeneity of AML. PDX
cells might resemble the wide variety of genetic subgroups within AML and thus serve as clini-
cally relevant model for drug testing. Furthermore, serial transplantation of PDX cells allows
repetitive and reproducible analyses with stable and defined patient samples, both for in vitro
and in vivo applications. However, three of the six samples allowing serial transplantation were
from patients with adverse-risk genetic features who had suffered relapse after allogeneic trans-
plantation, while the other three were from patients with newly diagnosed, ELN “Intermediate-
I” risk group AML. All but one patient died within twelve months after sample collection.
Therefore and as a limitation of the model, aggressive AMLs derived from adverse-risk patients
might be especially suitable for allowing serial transplantation in NSG mice, consistent with
data concerning initial engraftment capacity [11,19].
In vivo Imaging of Xenografted Patients' AML Cells
PLOS ONE | DOI:10.1371/journal.pone.0120925 March 20, 2015 15 / 20
So far, molecular studies in AML were restricted to AML cell lines, as PDX AML cells were
not systematically generated and genetic engineering was never performed in PDX AML cells.
Our protocol for lentiviral transduction of PDX AML cells will allow multiple molecular stud-
ies, to gain a deeper and clinically more relevant understanding of AML biology.
So far, using the individualized xenograft mouse model of AML for preclinical treatment tri-
als was hampered by the inability to sensitively and repetitively monitor disease progression.
Drug effects were determined post mortem [27], or at single time points using BM aspirates
[25,26]. We introduced BLI as convenient and quantitative in vivo readout parameter for PDX
AML cells. BLI enabled sensitive, reliable and repetitive disease monitoring and reduces re-
quired mouse numbers. BLI represents a convenient, simple and fast method to quantify stem
cell frequencies.
In conclusion, we advanced the xenograft mouse model of patient-derived AML by intro-
ducing and controlling serial transplantation, genetic engineering and in vivo imaging. As char-
acterized patient cells are available repetitively and can be monitored in vivo in a highly
sensitive way, the improved model will enable detailed reproducible in vivo studies on AML bi-
ology and therapy in the future.
Supporting Information
S1 Fig. Reengraftment capacity is predicted by degree of initial engraftment. (A) Exemplary
FACS plots for staining of hCD33 hCD45 are presented for sample AML-372 PB (d61), BM
and spleen (both d66). (B) 17 of 29 samples engrafted in NSG mice, defined by more than 0.5%
hCD45+ hCD33+ cells within BM within 20 weeks after transplantation. 107 cells were re-in-
jected into next generation recipients and percentage of hCD45+ hCD33+ cells within BM
within 20 weeks was measured. Each mark visualizes data obtained from one patient sample.
(PDF)
S2 Fig. Serial transplantation of PDX AML cells. (A) PDX AML cells which successfully en-
grafted in first recipients were re-isolated and serially transplanted into further recipient mice.
Waved closure: in progress at time of manuscript preparation; black line: no re-engraftment
could be observed after first re-transplantation in AML-373. (B) Serial transplantation of PDX
samples was analyzed regarding passaging time (defined as time period from cell injection
until animal death due to leukemia) and percentage or absolute number of cells positive for
both hCD45 and hCD33 at time of sacrifice within mouse PB, BM, or spleen, respectively.
Each mark visualizes data obtained from a single mouse. Cross: Not determined.
(PDF)
S3 Fig. Molecular stability of PDX AML cells. (A) Immunophenotype of primary cells and
PDX cells after four retransplantation cycles was analyzed by multicolour flow cytometry; spe-
cific fluorescence intensity of six AML associated antigens and of the aberrantly expressed anti-
gen CD7 (AML-361) is depicted. Raw data is depicted in S3 Table. (B) Difference in SFI of six
antigens analyzed of PDX cells after four retransplantation cycles or transgenic PDX cells and
primary specimens is depicted. ND: not determined. (C) Exemplary FACS plots for staining of
AML related antigens are presented for sample AML-372; for each antigen, isotype control
(grey lines) and specific staining (colored lines) is shown.
(PDF)
S4 Fig. Characterization of t-PDX AML cells. (A) t-PDX AML cells show similar growth be-
havior as non-transgenic PDX cells. t-PDX cells (white bars) were compared to PDX cells
(black bars) regarding passaging time and percentage or absolute number of cells positive for
both hCD45 and hCD33 at time of sacrifice within mouse PB or spleen, respectively; shown are
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means +/- standard deviation. (B) Transgene expression remains stable over passaging. Expres-
sion of mCherry was analyzed by flow cytometry directly after cell enrichment by flow cytome-
try and cell amplification in mice, and after additional one, two or four
retransplantation cycles.
(PDF)
S5 Fig. Highly sensitive repetitive BLI of t-PDX AML-372 cells in single mice. Additional
time points and reduced color scale to visualize lower BLI signals for the growth kinetics
shown in Fig. 4A (A) and Fig. 5A, 3x104 cells (B).
(PDF)
S6 Fig. BLI for quantifying leukemia stem cell surrogates. LDTA was performed in AML-
346 and monitored by BLI as depicted in S6 Table. If BLI showed a positive signal in two inde-
pendent measurements, mice were sacrificed as engraftment was proven. BLI-negative animals
were followed up until day 98, when mice were sacrificed; no hCD45 and hCD33 expressing
cells were detected by flow cytometry in BM of BLI negative mice. LIC frequency was quanti-






S1 Table. Genes analyzed by targeted next generation deep sequencing.
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S2 Table. Variant Allele Frequencies of mutations in AML specimens and PDX cells.
(PDF)
S3 Table. Immunophenotype of primary specimens and matched PDX cells.
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S4 Table. Clinical characteristics of pediatric AML patients.
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S5 Table. Ratio of BLI-positive mice after indicated time points after AML-372 injection.
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S6 Table. Ratio of BLI-positive mice after indicated time points after AML-346 injection.
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